Stone M D, Hawthorne A B, Kerr D, Webster G, Hosking D J
University Hospital, Nottingham, England.
J Bone Miner Res. 1990 Dec;5(12):1231-5. doi: 10.1002/jbmr.5650051207.
Disodium pamidronate (APD) is a potent inhibitor of bone resorption, with less risk of defective mineralization than earlier bisphosphonates. We assessed the response to six spaced low-dose intravenous infusions of APD given at intervals of approximately 6 weeks followed by weekly infusions if bone turnover remained abnormal. Three groups of 10 patients were studied, each group receiving infusions of 15, 30, or 45 mg. Hydroxyproline excretion fell by 62% and alkaline phosphatase was reduced by 72%, with no difference between the dose levels. A total of 21 patients (70%) achieved normal levels of bone turnover, indicating that low-dose infusions of APD are a safe and effective treatment for Paget's disease.
帕米膦酸二钠(APD)是一种强效的骨吸收抑制剂,与早期的双膦酸盐相比,其矿化缺陷风险更低。我们评估了给予六次间隔约6周的低剂量静脉输注APD后的反应,如果骨转换仍异常,则随后每周输注。研究了三组,每组10名患者,每组接受15、30或45毫克的输注。羟脯氨酸排泄量下降了62%,碱性磷酸酶降低了72%,各剂量水平之间无差异。共有21名患者(70%)实现了骨转换水平正常,表明低剂量输注APD是治疗佩吉特病的一种安全有效的方法。